digital-pathology-2016_posters-accepted-abstracts

12 / 19

Page 51
Digital Pathology & Pathologists 2016
December 05-06, 2016
Volume 6 Issue 5(Suppl) J Clin Exp Pathol
ISSN: 2161-0681 JCEP, an open access journal
conferenceseries .com
December 05-06, 2016 Madrid, Spain
9th World Digital Pathology & Pathologists Congress
J Clin Exp Pathol 2016, 6:5(Suppl)
Characterizing changes in expression of EMT and metabolic markers during hematogenous
dissemination in breast cancer
Rafael Malagoli Rocha
Federal University of São Paulo, Brazil
Epithelial to Mesenchymal Transition (EMT) and metabolic reprogramming contribute to cancer progression. Here we
investigated changes in expression of EMT and metabolic markers during hematogenous dissemination of breast cancer.
So, we have performed analysis of EMT (CKs and FOXC1) and metabolic (PGC-1a, COXIV and MCT4) markers in CTCs
and tissue samples from naive non-metastatic patients (M0) and metastatic breast cancer patients undergoing therapy (M+).
As results, FOXC1 expression was higher in primary tumors than in their correspondent metastases (p=1.15e-4 ). Primary
tumors of M+ patients had lower expression of CKs compared to primaries of M0 patients. Both EMT markers were less
predominant in CTCs of M+ patients. CTCFOXC1+ in M+ patients was associated with HER-2+ primary (p=0.004) and T4
tumors (p=0.036). Positivity for markers of oxidative metabolism, PGC-1a and COXIV, was significantly higher in CTCs
from both M0 and M+ groups when compared to MCT4, an aerobic glycolysis marker. M0 patients presenting CTCMCT4- and
CTCPGC1a+/COXIV+ had shorter progression-free survival (p=0.026). In metastasis, PGC-1a expression was increased while MCT4
was decreased, in comparison to correspondent primary tumors. CTC count and expression of EMT markers changed in
CTCs after neoadjuvant therapy while metabolic characteristics were maintained. PGC-1a was the only metabolic marker
that presented positivity in CTCs before and after neoadjuvant treatment. This marker also showed increased expression in
primary tumor post treatment in one patient. Low or no correlation between CTCs and tumors has been observed for all
markers. In this sense, EMT and MET features can be observed in primary tumors and metastasis, respectively and these
phenomena can be subjected to alterations by neoadjuvant treatment. The predominance of oxidative metabolism profile in
CTCs and metastasis in contrast to aerobic glycolysis in primary tumor suggests that cancer cells reprogram their metabolism
from an aerobic glycolysis profile to an oxidative metabolism in order to supply their energetic demand for hematogeneous
dissemination. These events can be modulated by neoadjuvant therapy, pointing out metabolic pathways as potential target
sites. Furthermore, metastasis is the most common cause of mortality in cancer patients. Therefore, characterization of
processes that contribute for the dissemination of tumor cells represents an important approach for impairing colonization of
new sites. Here we described changes in expression of EMT and metabolic markers using representative samples of different
stages of breast cancer progression: CTCs, primary tumors and metastases. Our data point out CTCs and targeting metabolic
pathway as additional therapeutic targets in breast cancer as well as the further investigation of HER2 and FOXC1 connections
for understanding and modulation of EMT process in breast cancer.